Credit Suisse Assumes Ventyx Biosciences at Outperform, Announces Price Target of $63
Portfolio Pulse from richadhand@benzinga.com
Credit Suisse analyst Tiago Fauth assumes Ventyx Biosciences (NASDAQ:VTYX) with an Outperform rating and announces a price target of $63.
June 14, 2023 | 9:21 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Credit Suisse analyst Tiago Fauth assumes Ventyx Biosciences with an Outperform rating and a price target of $63.
The Outperform rating and price target of $63 by Credit Suisse analyst Tiago Fauth indicate a positive outlook for Ventyx Biosciences. This news is likely to have a positive impact on the stock price in the short term as it suggests that the analyst believes the stock will outperform the market.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100